AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Peripheral Blood Stem Cell TransplantationTransplantation, AutologousHematopoietic Stem Cell TransplantationCombined Modality TherapyHematopoietic Stem Cell MobilizationTransplantation ConditioningTransplantation, HomologousMelphalanGranulocyte Colony-Stimulating FactorAntineoplastic Combined Chemotherapy ProtocolsLeukapheresisHematologic NeoplasmsAntigens, CD34Blood Component RemovalCyclophosphamideStem Cell TransplantationMultiple MyelomaTreatment OutcomeMyeloablative AgonistsBusulfanGraft vs Host DiseaseNephritisLymphoma, Non-HodgkinEtoposideBone Marrow TransplantationGraft SurvivalThiotepaHematopoietic Stem CellsRemission InductionAntineoplastic Agents, AlkylatingRecurrenceCarmustineVincristineCytophagocytosisSalvage TherapyIfosfamideDisease-Free SurvivalHodgkin DiseaseAmyloidosisCytarabineStem CellsHematopoiesisSurvival RateCord Blood Stem Cell TransplantationDoxorubicinSurvival AnalysisNeoplasmsRetrospective StudiesTransplantation ChimeraTissue DonorsWhole-Body IrradiationTime FactorsCarboplatinInfectionLymphoma, T-CellPrednisoneGlomerulonephritisAntineoplastic AgentsKidney GlomerulusPlatelet CountHistocompatibilityPOEMS SyndromeProteinuriaHistocompatibility TestingFollow-Up StudiesLeukemia, Myeloid, AcuteImmunosuppressive AgentsDexamethasoneTransplantation, IsogeneicVidarabineBlood Cell CountRecombinant ProteinsProspective StudiesLeukemiaBone Marrow PurgingComplement C3LymphomaBlood Transfusion, AutologousFeasibility StudiesFatal OutcomeBlood CellsCytomegalovirus InfectionsGraft vs Leukemia EffectBasement MembraneBreast NeoplasmsPrognosisMyelodysplastic SyndromesImmunophenotypingAnemia, AplasticLeukemia, Myelogenous, Chronic, BCR-ABL PositiveT-LymphocytesLiver TransplantationLymphocyte DepletionMethotrexateLeukocytes, MononuclearPrecursor Cell Lymphoblastic Leukemia-LymphomaHematologic DiseasesBone MarrowOpportunistic InfectionsHistiocytosis, Non-Langerhans-Cell
LymphomaGranulocyte-macropTransplantMultiple myelomaMarrowHSCTPatient'sRegimensProgenitorTumor cellsSurgical resectionMelphalanLymphoidDLBCLAcute myelogenRegimenDonorDosesLymphomasTransplantsGraft-versus-AntigensConventional chemotherapyNonmyeloablative allogeneicRenal cell carcAbstractEfficacyTherapiesTreatment with chemotherapyInduction chemotherapyImmunotherapySurvivalEtoposidePost-transplantationRadiationOutcomesUmbilical cordTherapyPlus chemotherapyRelapseImmuneDoseTherapeuticLymphocytesClinicalLymphoproliferative disordersCyclophosphamide
Lymphoma47
  • This ulcerated nodule of localized primary cutaneous CD30+ anaplastic large cell lymphoma is relatively nonspecific in appearance. (medscape.com)
  • The diagnosis of diffuse large cell lymphoma is usually confirmed after positive findings are obtained from a lymph node biopsy specimen. (medscape.com)
  • It will also describe rare forms of panniculitis, such as Eosinophilic panniculitis (a pathological entity debated by many authors), Subcutaneous panniculitis T-cell lymphoma, and the different forms of the so call "Lipophagic panniculitis", encompassing respectively the febrile relapsing panniculitis of Weber-Christian disease and the non-relapsing form of Rothmann-Makai disease. (bvsalud.org)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • Approximately 70 percent are B-cell lymphoma. (wikipedia.org)
  • Lymphoma is the most common cancerous cause of hypercalcemia (high blood calcium levels) in dogs. (wikipedia.org)
  • Multicentric lymphoma presents as painless enlargement of the peripheral lymph nodes. (wikipedia.org)
  • Gastrointestinal lymphoma causes vomiting, diarrhea, and melena (digested blood in the stool). (wikipedia.org)
  • Lymphoma in the bone marrow causes anemia, low platelet count, and low white blood cell count. (wikipedia.org)
  • There are now a range of blood tests that can be utilised to aid in the diagnosis of lymphoma. (wikipedia.org)
  • The canine Lymphoma Blood Test (cLBT) measures multiple circulating biomarkers and utilises a complex algorithm to diagnose lymphoma. (wikipedia.org)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Treatment for Hodgkin lymphoma (HL) is tailored to each individual and may include surgery, radiation therapy, chemotherapy, precision cancer medicines and or stem cell transplant in selected situations. (hoapb.com)
  • Chemotherapy alone or combined modality treatment with chemotherapy and radiation therapy is typically utilized even for early stage lymphoma. (hoapb.com)
  • A stem cell transplant is often the best option to treat blood cancers, such as leukemia , lymphoma and multiple myeloma , as well as bone marrow failure syndromes like myelodysplastic syndrome . (mdanderson.org)
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • Serum Levels of the Chemokine CXCL13, Genetic Variation in CXCL13 and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. (medscape.com)
  • Autologous T cells genetically modified to express CARs targeting the B-cell antigen B-lymphocyte antigen CD19 (CD19) have caused complete remissions in a small number of patients with leukemia or lymphoma. (survivornet.com)
  • Additionally, the positive data from the ECHELON-2 trial demonstrated that in patients with previously untreated CD30-positive peripheral T-cell lymphoma, ADCETRIS in combination with chemotherapy was superior to the control arm for progression-free survival and overall survival, representing an important milestone for ADCETRIS as a potential therapy in this setting where standard of care has not changed in several decades. (covaipost.com)
  • Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial. (cancernetwork.com)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. (biomedcentral.com)
  • In the nodal T cell lymphomas, the major subtypes are PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and ALK-negative ALCL. (biomedcentral.com)
  • 3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
  • Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
  • This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. (ucdavis.edu)
  • This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). (ucdavis.edu)
  • It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma. (ucdavis.edu)
  • Is radioimmunotherapy before a donor peripheral blood stem cell transplant an effective treatment for non-Hodgkin's Lymphoma? (ucdavis.edu)
  • This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma. (ucdavis.edu)
  • Safety, tolerability, toxicity management, and supportive care are important aspects of patient counseling in the treatment of diffuse large B-cell lymphoma (DLBCL). (expertperspectives.com)
  • Validation of the ΔSUV for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial. (canceropole-est.org)
  • Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. (canceropole-est.org)
  • Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry. (canceropole-est.org)
  • Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. (canceropole-est.org)
  • Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study. (canceropole-est.org)
Granulocyte-macrop1
Transplant30
  • A hematopoietic stem cell transplant replaces faulty cells so the body can produce normal, healthy cells again. (mdanderson.org)
  • An autologous stem cell transplant uses the patient's own cells for treatment. (mdanderson.org)
  • An allogeneic stem cell transplant is similar, but we take cells from someone other than the patient. (mdanderson.org)
  • Where do allogeneic stem cell transplant donor cells come from? (mdanderson.org)
  • With a peripheral blood cell transplant, the donor receives growth factor shots to stimulate the bone marrow to push the stem cells into the blood. (mdanderson.org)
  • The cells for a cord blood transplant come from an umbilical cord collected at birth by the MD Anderson Cord Blood Bank . (mdanderson.org)
  • For many patients who don't have a well-matched, healthy donor, a cord blood transplant is a viable option. (mdanderson.org)
  • These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity [31]. (slideshare.net)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • In the single autologous HCT arm, 129 of the 179 patients were subsequently given dinutuximab, an anti-GD2 monoclonal antibody, plus cytokine immunotherapy after single transplant consolidation therapy. (oncologynurseadvisor.com)
  • Positive data from the TOURMALINE-MM3 trial, the first and only Phase 3 placebo-controlled study evaluating a proteasome inhibitor in this setting, showed that using NINLARO as a post-autologous stem cell transplant maintenance treatment improved progression-free survival over the control arm, highlighting NINLARO's potential use as a maintenance therapy in a patient population where there are currently limited options. (covaipost.com)
  • At this year's ASH meeting, data from the Phase 3 TOURMALINE-MM3 trial, evaluating the effect of NINLARO (ixazomib) as a maintenance therapy in adult patients diagnosed with multiple myeloma who responded to high-dose therapy (HDT) and autologous stem cell transplant (ASCT), will be presented for the first time during an oral session on Sunday, December 2 at 7:30 a.m. (covaipost.com)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
  • Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
  • The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points. (mayo.edu)
  • The primary purpose of this study is to demonstrate the feasibility of sublingual (SL) administration of tacrolimus in blood and marrow transplant (BMT) patients. (mayo.edu)
  • The aim of this study is to measure the differences in quality of life and mood of hematopoietic stem cell transplant (HCT) patients and their caregivers staying at a hospital hospitality house (HHH), such as the Gift of Life Transplant House, the Help in Healing Home, and the Gabriel House of Care versus staying at a hotel/rental apartment or house. (mayo.edu)
  • Brief Summary RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the growth of cancer cells. (projectdatasphere.org)
  • It is not yet known whether combination chemotherapy is more effective with or without gemtuzumab ozogamicin followed by stem cell transplant in treating acute myeloid leukemia. (projectdatasphere.org)
  • PURPOSE: This randomized phase III trial is studying combination chemotherapy, gemtuzumab ozogamicin, and stem cell transplant to see how well they work compared to combination chemotherapy and peripheral stem cell transplant alone in treating patients with acute myeloid leukemia. (projectdatasphere.org)
  • Before transplant, stem cells are taken from patients and stored. (ucdavis.edu)
  • Giving rituximab, antithymocyte globulin, and total-lymphoid irradiation (TLI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. (ucdavis.edu)
  • A stem cell transplant is a procedure in which a person receives blood stem cells, which make any type of blood cell. (scdstudies.com)
  • Note: For transplant-eligible patients enrolled to Part 1 or Part 2, induction plus conditioning chemotherapy/ASCT +/- maintenance therapy constitute one regimen. (who.int)
Multiple myeloma9
Marrow27
HSCT14
  • Second-line chemotherapy regimens vary, depending on whether hematopoietic stem cell transplantation (HSCT) is being considered. (medscape.com)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • and phase mended strategies for preventing OIs in HSCT patients. (cdc.gov)
  • 3, the late phase (1100 days post-HSCT). (cdc.gov)
  • PHASES OF IMMUNE RECOVERY specialists, HSCT unit and clinic staff, and public health pro- fessionals. (cdc.gov)
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • The mediannumber of chemotherapy regimens was 2 after tositumomab/iodine-131 tositumomaband prior to HSCT (range: 1-4). (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy. (mayo.edu)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
Patient's10
  • In cases where such donors are not available, the process can extend to non-related donors or even a patient's own cells, demonstrating the flexibility and innovation inherent in this field. (medistateinternational.com)
  • It permits the administration of exceedingly high doses of chemotherapy, a practice that becomes viable due to the subsequent infusion of the patient's own stem cells. (medistateinternational.com)
  • The patient has low blood counts until the replaced cells replenish the patient's body with healthy cells. (mdanderson.org)
  • The transplanted cells kill any remaining cancer cells and restore the patient's immune system. (mdanderson.org)
  • If the donor cells aren't a close enough match, the patient's body may recognize the donor cells as foreign and reject them. (mdanderson.org)
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • Clinical trials performed during the 1980's have shown that treatment of localized osteosarcoma with adjuvant chemotherapy improves a patient's chance of survival and decreases the risk of cancer recurrence compared to surgery alone. (radiationoncologyassociates.co)
  • It also helps stop the patient's immune system from rejecting the transplanted stem cells. (projectdatasphere.org)
  • If the patient's stem cells are to be transplanted, the patient is also treated with a monoclonal antibody, such as gemtuzumab ozogamicin, to kill any remaining cancer cells or deliver cancer-killing substances to them without harming normal cells. (projectdatasphere.org)
  • The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1. (ucdavis.edu)
Regimens5
  • These findings demonstrate that bortezomib is safe and has a potential role in conditioning regimens in combination with BuMel for patients with transplantation-eligible MM. (elsevierpure.com)
  • Although combination chemotherapy regimens, including the nucleoside analogue fludarabine, were once the most commonly used first-line therapy in CLL, non-chemotherapy regimens (eg, with Bruton tyrosine kinase [BTK] inhibitors) are currently preferred in most cases. (medscape.com)
  • Patients received a median of 3(range: 2-6) prior chemotherapy regimens (exclusive of tositumomab/iodine-131tositumomab) before or after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • These are intensive chemotherapy regimens that, on one level, serve to identify patients who can tolerate such therapy, and they may offer potent cytoreduction, with the quality of remission being the biggest predictor of success with subsequent high-dose chemotherapy and autologous stem cell transplantation. (expertperspectives.com)
  • Conditioning regimens are treatments used to prepare a patient for stem cell transplantation. (scdstudies.com)
Progenitor3
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
Tumor cells7
  • ALCL was recognized in 1985, when tumor cells consistently demonstrated labeling by the monoclonal antibody Ki-1, a marker later shown to recognize the CD30 antigen. (medscape.com)
  • Moreover, increasing data have shown that peripheral T-cell tolerance is an essential property of the specific immune response to tumor cells. (biomedcentral.com)
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
  • Agents in this class halt the cell cycle at the G1 phase in tumor cells. (medscape.com)
  • Researchers hope the changed T cells will be better at recognizing and killing tumor cells. (survivornet.com)
Surgical resection2
Melphalan4
Lymphoid2
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • indicated that ATMs colocalized with T cells in lymphoid clusters within adipose tissue and may act as APCs, which express high levels of MHCII and also costimulatory molecules and process and present antigens to induce CD4+ T-cell proliferation and activation in adipose tissue of obese mice (29, 68, 105). (exposed-skin-care.net)
DLBCL3
  • A study by Salles et al determined that correlations between specific biomarkers and the international prognostic index (IPI) score demonstrate that IPI remains the best available index in patients with DLBCL treated with rituximab and chemotherapy. (medscape.com)
  • Outcome data are in line with previously reported studies, especially the data for salvage treatment and BEAM conditioning in DLBCL patients confirmed the outcome reported recently in a phase III study. (smw.ch)
  • Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study. (canceropole-est.org)
Acute myelogen1
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
Regimen1
  • A conditioning regimen may include chemotherapy, monoclonal antibody therapy, and radiation to the entire body. (scdstudies.com)
Donor8
  • In such cases, the transplantation procedure is prioritized during the early stages, provided a suitable donor is identified. (medistateinternational.com)
  • The decision to proceed with stem cell transplantation for these conditions hinges on a comprehensive evaluation of the disease's course, severity, donor-related attributes, and procedural risks. (medistateinternational.com)
  • The success of stem cell transplantation pivots on the identification of a donor possessing either a fully-matched or partially-matched tissue group with the patient. (medistateinternational.com)
  • This allows us to collect more cells in a short period, decrease patient/donor downtime and freeze the cells for future use. (mdanderson.org)
  • Or, the cells from the donor may recognize the new body as foreign and attack. (mdanderson.org)
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
  • Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
  • This way of making iPSCs from adult cells circumvents the need to destroy an embryo from living donor. (bmrat.org)
Doses3
  • In phase I, doses of bortezomib (.7, 1.0, and 1.3 mg/m 2 ) with BuMel were administered to groups of 3 patients each. (elsevierpure.com)
  • Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. (ucdavis.edu)
  • 2016). The high doses of chemotherapy used in al. (bvsalud.org)
Lymphomas3
  • Anaplastic large cell lymphomas (ALCLs) are distinguished from other lymphomas by their anaplastic cytology and constant membrane expression of the CD30 antigen (an activation marker for B or T cells). (medscape.com)
  • The International PTCL project that collected 1314 cases of T/NK-cell lymphomas from 22 institutions worldwide revealed that the most common subtypes worldwide are the nodal T cell lymphomas [ 2 ]. (biomedcentral.com)
  • however, outcomes are poor when PTCL is treated according to strategies established for aggressive B cell lymphomas [ 3 ]. (biomedcentral.com)
Transplants6
  • Citation: Mera T, Heimfeld S, Faustman DL (2014) The Spleen Contributes Stem Cells to Peripheral Blood Stem Cell Transplants. (fliphtml5.com)
  • For induce splenomegaly in most donors and in rare, severe cases splenicautologous stem cell transplants, the use of autologous PBSCT from rupture [13,14]. (fliphtml5.com)
  • To understand the different types of stem cell transplants and how they work, we spoke with Borje S. Andersson, M.D., Ph.D. Here's what he had to say. (mdanderson.org)
  • What are the types of stem cell transplants? (mdanderson.org)
  • Stem cell transplants fall into two categories: autologous and allogeneic. (mdanderson.org)
  • BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. (uchicago.edu)
Graft-versus-2
  • Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. (uchicago.edu)
  • Graft-versus-host disease (GVHD) is a complication that may occur after hematopoietic cell transplantation (HCT) in which donated cells view the recipient's cells as foreign and attack them. (scdstudies.com)
Antigens5
  • Sixty percent of cases express 1 or more T-cell antigens (CD3 + , CD43, or CD45RO). (medscape.com)
  • Flow cytometry detects antibodies linked to tumour cell surface antigens in fluid samples or cell suspensions. (wikipedia.org)
  • We all have protein structures called human leukocyte antigens (HLA) on our cells' surfaces. (mdanderson.org)
  • This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
  • T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens. (survivornet.com)
Conventional chemotherapy1
Nonmyeloablative allogeneic1
Renal cell carc1
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
Abstract1
  • Invited discussant for this abstract Dominique Valteau-Couanet, MD, PhD, head of the pediatric and adolescent oncology department at Institut Gustave Roussy in France, questioned which patients actually benefit from tandem autologous HCT: patients with localized disease and MYCN amplification? (oncologynurseadvisor.com)
Efficacy5
  • A subsequent cohort with 41 patients was analyzed in a phase II trial to identify safety and efficacy. (elsevierpure.com)
  • The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study. (kanazawa-u.ac.jp)
  • Because pilot studies of tandem autologous HCT demonstrated tolerable toxicity and potential efficacy and because prior trials have demonstrated that dose intensification improves outcomes, researchers decided to explore tandem transplantation in patients with high-risk neuroblastoma. (oncologynurseadvisor.com)
  • We investigated the safety and efficacy of immune suppression and autologous haemopoietic stem-cell infusion to treat such patients. (northwestern.edu)
  • The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003. (ucdavis.edu)
Therapies5
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • and the role of CAR T-cell therapy as it relates to HCT as therapies for R/R B-NHL. (jnccn.org)
  • Novel targeted therapies and combination chemotherapies are required for the treatment of patients with PTCL. (biomedcentral.com)
  • We decided to perform cord blood stem cell transplantation (CBSCT) for hematopoietic rescue after the myeloablative therapies. (biomedcentral.com)
  • Three chimeric antigen receptor (CAR) T-cell therapies are approved by the US Food and Drug Administration in the third-line setting: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. (expertperspectives.com)
Treatment with chemotherapy1
  • These rates are not comparable to the typical cure rates of treatment with chemotherapy and surgery together, indicating that treatment of osteosarcoma with chemotherapy alone is insufficient. (radiationoncologyassociates.co)
Induction chemotherapy1
  • All patients received multi-agent induction chemotherapy for 6 cycles, including an initial 2 cycles of high-dose cyclophosphamide plus topotecan followed by blood stem cell collection. (oncologynurseadvisor.com)
Immunotherapy5
  • The role of PD-1 and PD-L1 in T-cell immune suppression and the potential for immunotherapy via blocking PD-1 and PD-L1 in hematological malignancies are also reviewed. (biomedcentral.com)
  • Systemic therapy is any treatment directed at destroying cancer cells throughout the body and may include chemotherapy, immunotherapy or newer precision cancer medicines. (hoapb.com)
  • Cancer cells are very good at finding ways to avoid immune destruction, however, so the goal of immunotherapy is to help the immune system eliminate cancer cells by either activating the immune system directly or inhibiting the mechanisms of suppression of the cancer. (hoapb.com)
  • The study further demonstrated that tandem autologous HCT also benefits patients who received immunotherapy, with a significant difference in 3-year event-free survival between the 2 treatment arms ( P =.0033). (oncologynurseadvisor.com)
  • In- duced pluripotent stem cells have been used to create active T cells to support cancer immunotherapy. (bmrat.org)
Survival3
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • Early initiation of chemotherapy has failed to show survival benefit in CLL. (medscape.com)
  • Results showed that 3-year event-free survival was 48.4% ± 3.8% with single autologous HCT compared with 61.4% ± 3.7% with tandem autologous HCT ( P =.0081). (oncologynurseadvisor.com)
Etoposide1
  • After 4 cycles of chemotherapy with topotecan and etoposide, 131 I-MIBG treatment was performed at a dose of 18 mCi/kg. (biomedcentral.com)
Post-transplantation1
  • For post-transplantation best response, an 83% rate of VGPR or better (68% CR) was observed. (elsevierpure.com)
Radiation7
  • Radiation therapy uses high-powered energy beams, such as X-rays or protons, to kill cancer cells. (hoapb.com)
  • The objective of radiation therapy is to kill cancer cells for a maximum probability of cure with a minimum of side effects. (hoapb.com)
  • Radiation is usually given in the form of high-energy beams that deposit the radiation dose into the body where cancer cells are located. (hoapb.com)
  • Radiation therapy, unlike chemotherapy, is considered a local treatment. (hoapb.com)
  • Cancer cells can only be killed where the actual radiation is delivered to the body. (hoapb.com)
  • If cancer exists outside the radiation field, the cancer cells are not destroyed by the radiation. (hoapb.com)
  • For a long time, stem cells have been utilized to renew the immune system for radiation or chemo- therapy treated patients. (bmrat.org)
Outcomes4
  • HCT, whether it be autologous, allogeneic, or tandem, has been and continues to be an integral part of therapy, with varying outcomes as delineated in Table 2 . (jnccn.org)
  • Research shows that chemotherapy without surgery results in worse outcomes. (radiationoncologyassociates.co)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
Umbilical cord2
  • peripheral blood, or placental/umbilical cord blood). (cdc.gov)
  • and umbilical cord blood (PUCB), capable of 2017), associated with the results of the procedure restoring spinal cord function and immunology of and require a process of hospitalization and patients with indication for transplantation, with the prolonged hospital recovery. (bvsalud.org)
Therapy14
  • The decision to proceed with transplantation hinges on a thorough assessment of patients' chances for successful results, along with a comprehensive understanding of therapy-related risks. (medistateinternational.com)
  • This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction therapy. (biomedcentral.com)
  • PBSC mobilization should be performed after induction therapy to ensure collection of a sufficient number of cells. (biomedcentral.com)
  • In Section II, Dr. James Griffin reviews the mechanisms that lead to activation of tyrosine kinases by mutations in AML, the consequences of that activation for the cell, and the opportunities for targeted therapy and discusses some examples of developing novel drugs (tyrosine kinase inhibitors) and their effectiveness in AML (FLT3). (ashpublications.org)
  • Once a genetic abnormality is identified, a specific targeted therapy can be designed to attack a specific mutation or other cancer-related change in the DNA programming of the cancer cells. (hoapb.com)
  • Allogeneic stem cell transplantation is the only known curative therapy for CLL. (medscape.com)
  • This review outlines the disparate types of stem cell therapy that have been used in this difficult-to-treat population as well as the role of maintenance and CAR T-cell therapy in conjunction with stem cell therapy. (jnccn.org)
  • Systemic therapy is treatment directed at eliminating cancer cells throughout the body, and usually consists of chemotherapy. (radiationoncologyassociates.co)
  • Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
  • A Phase 2, multi-centre, multiple dose, open label trial without a control will investigate the application of erythrocyte-encapsulated thymidine phosphorylase (EE-TP) as an enzyme replacement therapy for MNGIE. (encyclopedia.pub)
  • Iodine-131-metaiodiobenzylguanidine ( 131 I-MIBG) therapy combined with allogeneic cord blood stem cell transplantation (SCT) was used to treat a 4-year-old girl with recurrent neuroblastoma. (biomedcentral.com)
  • In gene therapy, small stretches of deoxyribonucleic acid (DNA) called 'anti-HIV genes' are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. (ucdavis.edu)
  • Special advances are achieved in HER-positive tumors using targeted therapy with drugs which suppress the tumor cell growth factors (trastuzumab, herceptin). (cttjournal.com)
  • Although there was evidence of a response to CTD (M-protein 34 g/L), bortezomib and dexamethasone treatment was initiated as an alternative, but this was discontinued after three cycles due to progressive disease (M-protein 49 g/L). The patient was then treated with lenalidomide and dexamethasone with the aim of reducing disease burden prior to high-dose therapy and autologous stem cell transplantation. (bmj.com)
Plus chemotherapy1
  • The FDA has set a Prescription Drug User Fee Act date of April 5, 2024 for nivolumab plus chemotherapy in unresectable or metastatic urothelial carcinoma. (cancernetwork.com)
Relapse2
  • In addition, PD-1/PD-L1 interactions contribute to functional T-cell impairment, which fails to elicit minimal residual disease and may be related to leukemia relapse. (biomedcentral.com)
  • National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
Immune7
  • Such immune dysfunction may be due to a disorder in thymic output function (in particular in young patients), which results in a lower level of naive T-cells in the peripheral blood available for an immune response to the proliferation and abnormal expression of the T cell receptor (TCR) repertoire. (biomedcentral.com)
  • The immune system is a network of cells, tissues, and biologic substances that defend the body against viruses, bacteria, and cancer. (hoapb.com)
  • The immune system recognizes cancer cells as foreign and can eliminate them or keep them in check-up to a point. (hoapb.com)
  • One type creates a new, individualized treatment for each patient by removing some of the person's immune cells, altering them genetically to kill cancer, and then infusing them back into the bloodstream the other uses precision medications to enhance the immune systems response to the cancer. (hoapb.com)
  • PD-1 and PD-L1 are proteins that inhibit certain types of immune responses, allowing cancer cells to evade detection and attack by certain immune cells in the body. (hoapb.com)
  • Patients underwent dose-intense immune suppression and autologous haemopoietic stem-cell (CD34) infusion. (northwestern.edu)
  • It uses a person s own T cells, which are part of the immune system. (survivornet.com)
Dose6
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • We extract blood cells, treat the cancer with high-dose chemotherapy , then place the cells back into the patient. (mdanderson.org)
  • The remaining seven received high-dose chemotherapy and stem-cell infusion. (northwestern.edu)
  • Loncastuximab tesirine is an anti-CD19 antibody-drug conjugate that has a unique toxicity profile in that it can produce liver function test elevations (gamma-glutamyltransferase), peripheral edema, or a capillary leak-like syndrome that appears to be dose dependent and potentially cumulative. (expertperspectives.com)
  • Two died while receiving high-dose systemic corticosteroids, methotrexate, and after recent exposure to anti-tumor necrosis factor-α biological DMARDs, and 2 during hematopoietic stem cell transplantation procedure. (cdc.gov)
  • Treatment was frequently interrupted and dose adjusted to account for neutropenia and despite a minor response after six cycles (starting M-protein 47 g/L, finishing M-protein 34 g/L), in October 2009, she proceeded with stem cell mobilisation. (bmj.com)
Therapeutic3
  • However, during stem cell mobilization and -collection, no study-specific therapeutic intervention was performed. (biomedcentral.com)
  • With the presentation of data from two Phase 3 clinical trials as well as our pipeline, Takeda continues to grow the body of evidence for new therapeutic options that improve the way in which we treat blood cancer patients," said Christophe Bianchi, M.D., President, Takeda Global Oncology Business Unit. (covaipost.com)
  • Recently, stem cells are being engineered to carry therapeutic reagents to target tumor sites. (bmrat.org)
Lymphocytes4
  • Samples of peripheral blood lymphocytes (PBLs) were obtained from ten normal untreateddonors and 18 normal donors treated with G-CSF. (fliphtml5.com)
  • Peripheral blood lymphocytes were analysed by flow cytometry, ELISA, and T-cell-receptor spectratyping before and after transplantation. (northwestern.edu)
  • Another statement showed the preadipocyte- and endothelial cell-derived stromal-derived element-1 (CXCL12), mediated early infiltration of CD4+ T lymphocytes in obesity, which preceded the increase of macrophages in adipose cells of mice on HFD (101). (exposed-skin-care.net)
  • In obese humans, adipocyte-secreted CCL20 may contribute to the deposition of Compact disc4+ helper and Compact disc8+ cytotoxic T lymphocytes within adipose tissues, possibly via connections with CCR6 which was upregulated on T cells in obese adipose tissues (100). (exposed-skin-care.net)
Clinical5
  • Patients were treated within the randomized phase III clinical trials GMMG-HD6 (NCT02495922, 24/06/2015) and GMMG-HD7 (NCT03617731, 24/07/2018). (biomedcentral.com)
  • Enrichment of PBSCT by purification of CD34+stem cells fails to produce superior clinical benefits. (fliphtml5.com)
  • The inferior clinical performance of CD34+-enriched and purified PBSCTs compared tounenriched PBSCTs may be explained by the omission of Hox11+ stem cells. (fliphtml5.com)
  • Notably, Takeda will present data from the Phase 3 TOURMALINE-MM3 and ECHELON-2 clinical trials. (covaipost.com)
  • The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials. (cancernetwork.com)
Lymphoproliferative disorders1
  • PC-ALCL is one of the primary cutaneous CD30 + T-cell lymphoproliferative disorders, a wide spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end of the spectrum and PC-ALCL at the malignant end. (medscape.com)
Cyclophosphamide1